## **Prior Authorization Form**



**Note:** Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information	Prescriber Information
Patient Name:	Prescriber Name:
Health Plan Name:	Prescriber Address:
Patient Insurance Id:	
Patient Date of Birth:	Prescriber Phone: ( )
Patient Phone:	Prescriber Fax: ( )
	Prescriber Specialty:
	Prescriber DEA:
	Prescriber NPI:
Medica	ation & Medical Information
Requested Drug(s) & Strength(s):	[ ] dimethyl fumarate 120 mg (14)-240 mg (46) capsule,delayed release [ ] dimethyl fumarate 120 mg capsule,delayed release [ ] dimethyl fumarate 240 mg capsule,delayed release
Requested Daily Quantity Limit – Amount:	
Requested Daily Quantity Limit – Days:	
Requested Quantity Limit Over Time – Amount:	
Requested Quantity Limit Over Time – Days:	
Expected Length of Therapy:	
Directions:	
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):	
List drugs used previously to treat the same condition:	
Additional clinical information or history. Please include any relevant test results and/or medical record notes:	
	Questionnaire
	f the provider, certify and attest that the information provided is complete any information to RxAdvance that RxAdvance determines is reasonably at apply)
[] Yes	
[] No	
Q2: Is the member currently treated with this medica	ation? (Check only one that apply)
[ ] Yes (please list start date of therapy (month/(*Required)	day/year))

## **Prior Authorization Form**



[] No	
Q3: What is the member's diagnosis? (Check only one that apply)	
[] Relapsing form of Multiple Sclerosis (e.g., clinically isolated syndrodisease, including active disease with new brain lesions)	ome, relapsing-remitting disease, secondary progressive
[] Other (please specify the member's diagnosis and provide clinical(*Require	
Q4: Does the member have documentation of positive clinical response to clinical relapses, disease progression)? (Check only one that apply)	therapy (e.g., stability in radiologic disease activity,
[] Yes (please provide document(s) supporting positive response to(*Require	
[ ] No (please provide clinical rationale for the request for continuati (*Require	* * *
Q5: What is the member's diagnosis? (Check only one that apply)	
[] Relapsing form of Multiple Sclerosis (e.g., clinically isolated syndrodisease, including active disease with new brain lesions)	ome, relapsing-remitting disease, secondary progressive
[] Other (please specify the member's diagnosis and provide clinical(*Require	
Q6: Is the medication prescribed by or in consultation with an neurologist	? (Check only one that apply)
[] Yes	
[ ] No (please provide clinical rationale for the request)(*Required)	
Q7: Is the requested medication used in combination with another disease	e-modifying therapy for MS? (Check only one that apply)
[ ] Yes (please provide details)	(*Required)
[] No	
<u>Attestation:</u> I attest the information provided is true and accurate to the best of r Medical Group or its designated representatives may perform a routine audit and accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	